OncoMatch/Clinical Trials/NCT06680739
Single cEll pRofiling PErsistaNce To ImmuNothErapy
Is NCT06680739 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Durvalumab and Tremelimumab for colorectal cancer.
Treatment: Durvalumab · Tremelimumab — The SERPENTINE trial (ESR 21-21165) is a phase II clinical study aiming to evaluate the efficacy of durvalumab and tremelimumab, alone or in combination, in patients with colorectal or endometrial cancer. The trial targets patients with microsatellite instability-high (MSI-H) tumors and those with microsatellite stable (MSS) tumors. Colorectal and endometrial cancers present significant challenges due to their heterogeneity and variable responses to treatment. Immunotherapy, particularly checkpoint inhibitors like durvalumab and tremelimumab, has shown promise in some patients, but predicting response remains elusive. The SERPENTINE trial aims to address this gap by investigating the effectiveness of these immunotherapies in a carefully selected patient population.
Check if I qualifyExtracted eligibility criteria
Cancer type
Colorectal Cancer
Endometrial Cancer
Biomarker criteria
Allowed: EGFR positive
if epidermal growth factor receptor (EGFR) positive/RAS wild type, prior anti-EGFR treatment is required
Allowed: KRAS wild-type
if epidermal growth factor receptor (EGFR) positive/RAS wild type, prior anti-EGFR treatment is required
Allowed: NRAS wild-type
if epidermal growth factor receptor (EGFR) positive/RAS wild type, prior anti-EGFR treatment is required
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: fluoropyrimidine, irinotecan and/or oxaliplatin containing therapy with or without bevacizumab — advanced/metastatic CRC
progressed during or after, at least 2 lines of fluoropyrimidine, irinotecan and/or oxaliplatin containing therapy with or without bevacizumab according to institutional practice or have not tolerated therapy for advanced/metastatic disease
Must have received: anti-EGFR therapy — advanced/metastatic CRC, EGFR positive/RAS wild type
if epidermal growth factor receptor (EGFR) positive/RAS wild type, prior anti-EGFR treatment is required
Must have received: platinum and taxane-based regimen — advanced/metastatic endometrial cancer
progressed during or after a platinum and taxane-based regimen, not amenable to surgery
Cannot have received: anti-PD-1 therapy
Has previously received prior therapy with an anti-PD-1
Cannot have received: anti-PD-L1 therapy (durvalumab)
Has previously received prior therapy with ... anti-PD-L1 including durvalumab
Cannot have received: anti-CTLA-4 therapy (ipilimumab)
Has previously received prior therapy with ... anti CTLA-4 (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways)
Cannot have received: monoclonal antibody
Has had a prior anti-cancer mAb within 4 weeks prior to study Day 1
Cannot have received: chemotherapy, targeted small molecule therapy, hormonal therapy or radiation therapy
Has had prior chemotherapy, targeted small molecule therapy, hormonal therapy or radiation therapy for cancer therapy within 2 weeks prior to study Day 1
Lab requirements
Blood counts
Hemoglobin ≥9.0 g/dL; ANC ≥1500 per mm3; Platelet count ≥100 x 10^9/L (>75,000 per mm3)
Kidney function
Measured creatinine clearance (CL) >40 mL/min or Calculated creatinine CL>40 mL/min by Cockcroft-Gault or 24-hour urine collection; Creatinine ≤1.5 x ULN OR measured/calculated creatinine clearance ≥60 mL/min for subjects with creatinine >1.5 x ULN
Liver function
Serum bilirubin ≤1.5 x institutional ULN (except Gilbert's syndrome); AST (SGOT)/ALT (SGPT) ≤2.5 x ULN unless liver metastases present, then ≤5 x ULN
Adequate normal organ and marrow function as defined below: Hemoglobin ≥9.0 g/dL; ANC ≥1500 per mm3; Platelet count ≥100 x 10^9/L (>75,000 per mm3); Serum bilirubin ≤1.5 x institutional ULN (except Gilbert's syndrome); AST (SGOT)/ALT (SGPT) ≤2.5 x ULN unless liver metastases present, then ≤5 x ULN; Measured creatinine clearance (CL) >40 mL/min or Calculated creatinine CL>40 mL/min by Cockcroft-Gault or 24-hour urine collection; Creatinine ≤1.5 x ULN OR measured/calculated creatinine clearance ≥60 mL/min for subjects with creatinine >1.5 x ULN
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify